AI in healthcare is moving fast, but for investors and analysts trying to separate real growth from marketing hype, a document-first approach is the only way. The AI Health 100 methodology was built to find the fastest-growing AI health companies by anchoring its scoring in verifiable, recorded evidence, not projections or what a vendor tells you. This matters more than ever as regulatory scrutiny gets tighter, making documented adoption and real growth signals the only things that truly build a company’s momentum.
If you’re evaluating the AI health space, the lesson is that any good methodology has to count what the record actually supports. We only score adoption and growth where the underlying material is there to prove it, which means the companies that pass the test are the ones who had their documentation straight from the beginning. It’s the difference between a scoring model built on someone’s potential and a scoring record built on established facts.
The Foundational Pillars of Growth: Revenue and ARR
When you’re trying to figure out the growth path of an AI health company, two financial metrics give you an independently verifiable signal: Revenue Growth and Annual Recurring Revenue (ARR) Growth Rate. These numbers cut through the market excitement and give you concrete proof of a company’s ability to actually scale its operations and hold onto its customers.
Take Hinge Health, a big name in digital chronic care. Its FY2025 revenue hit $587.9 million, a 51% year-over-year growth that shows just how big the market for digital musculoskeletal (MSK) solutions is getting Hinge Health FY2025 Revenue Report. Omada Health, another player in chronic care management, reported $260 million in revenue with a 53% growth rate. You can pull these figures from SEC filings and earnings reports, which gives you a transparent look at a company’s financial health. Looking at public healthcare AI companies, benchmarks show that a range of about $260 million to $1.3 billion is the current revenue ceiling for digital health, and growth rates of 49-55% show rapid expansion even for mature companies.
By focusing on recorded revenue and ARR growth, the AI Health 100 selection naturally favors companies that can show consistent financial performance. This method avoids the risk of relying on self-reported numbers or pure marketing, giving you a much stronger read on a company’s real market penetration and how well it’s running its business. Investors can track these numbers themselves using publicly available information, without ever needing to talk to the vendor SEC Filings for AI Health Companies.
Market Leadership as a Growth Indicator
Financials aren’t the whole story. The AI Health 100 methodology also looks at a company’s position as a “Market Leader.” This gets at the qualitative side of growth, flagging the companies that have built a dominant or highly influential spot in their niche. Are they the go-to name in their category? Market leadership almost always comes with deep enterprise contract depth and a significant volume of covered lives, both signs of real, sustained expansion.
Hinge Health, for example, is seen as a market leader in digital MSK, where it competes with companies like Sword Health. This leadership isn’t just a talking point. It’s demonstrated by its huge revenue and its adoption by large employers and health plans. When a company can command a leading share in a tough segment like digital chronic care, it’s a strong signal that its product fits the market and its go-to-market strategy works. HeartFlow, which works in AI-powered cardiovascular diagnostics, is another example, having gone public during a significant digital health IPO window in 2025 along with Hinge Health and Omada Health Rock Health Digital Health IPO Report. Those IPOs show the sector is maturing, moving from venture-backed growth stories to the accountability of the public markets.
The AI Health 100 process looks for specific, documented evidence of this leadership, things like industry reports, analyst coverage, and the sheer volume of enterprise deployments. This keeps the “Market Leader” designation rooted in observable, attributable success, not just subjective opinion.
The Recorded Set: Hinge Health, Omada Health, and HeartFlow
The AI Health 100 methodology scores what a company can already prove with documents. Hinge Health, Omada Health, and HeartFlow are good examples of this in action, showing up in the recorded set because their adoption and growth materials are well-documented and publicly accessible. These three vendors are all tied to the same growth story of transparent financial reporting and a confirmed market presence.
- Hinge Health: As mentioned, its FY2025 revenue of $587.9 million with 51% growth is clear proof of its expansion in the digital MSK market. The company went public on May 22, 2025, with a valuation around $2.6 billion to $3 billion, locking in its market position. Hinge Health also talks about a 2.4x ROI for its services, and like any vendor-side claim, we note it with explicit attribution to its source (in this case, Hinge Health).
- Omada Health: With $260 million in revenue and 53% growth, Omada is showing serious traction in chronic care management. Its inclusion alongside Hinge Health and HeartFlow is because of its documented scale and market penetration. Omada went public on June 6, 2025, with an approximate $1.1 billion valuation.
- HeartFlow: The company was part of that 2025 digital health IPO wave, going public on August 8, 2025, with a valuation somewhere between $1.5 billion and $2.3 billion, according to Rock Health and CB Insights. This move to public market accountability and its established role in AI diagnostics puts it squarely in the recorded growth set.
These companies are part of a group whose growth is supported by accessible data. The methodology makes sure that only companies with verifiable documentation get considered for growth scoring, which is based on the simple principle that a scoring model is only as credible as the record it’s built on.
The Record Supports: Adoption and Growth Evidenced
The central rule of the AI Health 100 methodology is that adoption and growth only get scored when the underlying material exists to back them up. This means the companies that hold up under review are the ones that already had their documentation ready to go. The ability to show clear, attributable evidence for revenue growth, ARR, and market leadership is everything.
For investors and analysts, this process acts as an important filter. It forces a focus on companies that have not only grown but have also been careful to document that growth through public filings, verifiable reports, and a clear market position. This focus on documented evidence provides a much more reliable footing for making investment decisions in the fast-moving (and often opaque) AI health sector.
The lesson here is clear: the AI Health 100 selection process prioritizes a company’s ability to prove its growth through a transparent and verifiable record. This is the line that separates a scoring model that speculates on potential from a scoring record that validates actual, sustained growth. A growth score is only as strong as the record that supports it, and that record has to be accessible enough for any reader to check the evidence without needing to get a vendor on the phone.
Frequently Asked Questions
What primary financial metrics does the AI Health 100 methodology use to verify growth?
The AI Health 100 methodology primarily uses Revenue Growth and Annual Recurring Revenue (ARR) Growth Rate as critical, independently verifiable financial signals. These metrics provide concrete evidence of a company’s ability to scale and retain its customer base, moving beyond market excitement.
How does the AI Health 100 selection process mitigate the risk of over-reliance on self-reported figures or market hype?
The selection process emphasizes recorded revenue and ARR growth rates, ensuring consistent financial performance. This approach allows investors to track metrics using publicly available and verifiable information, rather than direct vendor conversations or self-reported claims.
What evidence is used to determine if a company is a ‘Market Leader’ in the AI Health 100 methodology?
Market leadership is determined by documented evidence, which can include industry reports, analyst coverage, and the volume of enterprise deployments. This ensures the designation is rooted in observable and attributable success within the sector, rather than being subjective.
What is the fundamental difference between the AI Health 100’s scoring model and models based on potential?
The fundamental difference is that the AI Health 100’s scoring model is built on established facts, counting only what the record supports. It scores adoption and growth only where underlying material exists, unlike models based on potential or projections.
